CLINICAL TRIALS ARTICLES
-
![Potter at work-GettyImages-1142834523]( "Beyond The Hype: How 2025's Successes & Realities Will Shape mRNA In 2026")
Beyond The Hype: How 2025's Successes & Realities Will Shape mRNA In 2026Here, in part two of this multi-part series, we hear from Melissa Bonner, CSO of nChroma Bio and Andy Geall, CDO of Replicate Biosciences, who call attention to several developments of the past year they’ve been watching and how they see these developments informing our conversations about and work with mRNA in 2026 and beyond.
-
![T-Cells Work to Fight Cancer, Immunotherapy, CAR T-cell therapy-GettyImages-1317697233]( "Overcoming CMC Challenges In The Development Of Conjugated LNP Platforms For In Vivo CAR-T Therapy")
Overcoming CMC Challenges In The Development Of Conjugated LNP Platforms For In Vivo CAR-T TherapyOvercoming CMC hurdles is key to advancing conjugated LNP platforms for in vivo CAR-T therapy, enabling scalable, precise mRNA delivery to T cells while maintaining stability, potency, and regulatory compliance.
-
![Bubble burst-GettyImages-1215335273]( "Beyond the Hype: Industry Experts on the Reality of mRNA in Cancer Care")
Beyond the Hype: Industry Experts on the Reality of mRNA in Cancer CareWhen I asked a panel of experts at RNA Leaders why mRNA was best positioned to shine in oncology, I was met with a few expected talking points and — better yet — a few I wasn’t expecting.
-
![Magnifying Glass, explain mechanism of mRNA vaccine-GettyImages-1903242094]( "Tackling Challenges In RNA Stability And Organ Targeting")
Tackling Challenges In RNA Stability And Organ TargetingRNA therapeutics are reshaping medicine, but instability and limited organ targeting still pose challenges. Discover how next-gen lipid nanoparticles and smart delivery systems are advancing RNA precision.
-
![Telemedicine, human Brain recovery-GettyImages-1397374666]( "Developing Exosome-Based RNA Therapeutics For CNS Regeneration")
Developing Exosome-Based RNA Therapeutics For CNS RegenerationInside the effort to use exosomes as natural nanocarriers that deliver RNA therapeutics safely across the blood–brain barrier to heal damaged neural tissue.
-
![Wealth-GettyImages-869781702]( "Bridging RNA Innovation: A CEO's Guide To European Expansion")
Bridging RNA Innovation: A CEO's Guide To European ExpansionFor RNA biotechs, Europe isn't just the next market — it's the ultimate test of strategy. Here's what CEOs need to know.
CLINICAL TRIALS VIDEOS
Hosted by Cell & Gene Collaborative Director Anna Rose Welch, ARW on RNA puts a creative spin on the emerging mRNA + RNA therapeutics industry. Here, in Episode 5, Welch dives into the separate — but strikingly similar — worlds of fly fishing and mRNA R&D. In particular, she explains how a fly fisherman’s strategies to catch a fish relate to the work of mRNA scientists as they strive to identify the most appropriate immunogenicity profiles for their mRNA vaccines or therapeutics.
Hosted by Cell & Gene Collaborative's Director Anna Rose Welch, ARW on RNA puts a creative spin on the emerging mRNA + RNA therapeutics industry. Here, in Episode 1, Welch draws a few connections between the magical world of Harry Potter and the challenging scientific work mRNA companies are doing today to explore and/or broaden mRNA's therapeutic potential in a variety of indications.
Gain valuable insights into the role of sponsor-side Clinical Operations leadership, the risks of over-relying on CROs, and key strategies for fostering collaboration between sponsors and partners.
This webinar discusses the expansion of International Market for Ensartini and RNAi Therapeutics in Oncology, from Skin Cancers to Liver Cancers.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![crossroad intersection railroad tracks-GettyImages-1582678578]( "Europe At A Crossroads: Biotech Investment, Regulation, And Partnership In Real Life")
Position your biotech for Europe’s next phase by aligning strong science, smart clinical strategy, and the right global partners to navigate funding, regulation, and growth.
-
Bioanalysis is crucial for biopharma success. Here, Dash Bio’s Ander Tallett discusses selecting a bioanalysis CRO and collaborating effectively for assay results that accelerate drug development.
-
Bioanalysis service quality significantly impacts project success. Don't settle for typical CRO claims; demand better technology, pricing transparency, and dedicated partnership.
-
![GettyImages-2006338804 conference]( "ESMO Congress 2025: Highlights From Berlin")
Turn the insights from this year’s ESMO into action by partnering to accelerate innovation through smarter trial design, stronger biomarker planning, and truly global collaboration.
-
![GettyImages-2152658176 oncology, doctor, patient]( "How Are Therapeutic Radiopharmaceuticals Advancing Precision Oncology?")
By directing radioactive isotopes straight to diseased tissue, these agents deliver potent, localized treatment while sparing healthy cells — a major leap forward for patients with metastatic or treatment-resistant cancers.
-
![Doctors board room meeting-GettyImages-1365555907]( "Highlights From The 2025 International Hepatitis B Meeting")
For biotech and pharmaceutical teams, the core message was clear: progress is accelerating, but success still depends on smart study design, fit-for-purpose endpoints, and operational execution.
-
![GettyImages-2010746888-clinical-meeting-tablet-collaboration]( "Therapeutic Radiopharmaceuticals: Clinical Research, CRO Enablers (2025)")
Accelerate the future of precision oncology by driving innovation, optimizing clinical development, and expanding access to targeted therapies that transform patient outcomes.
